Challenges in the use of the CytoSorb® adsorber in an intensive care patient with liver dysfunction of unknown origin: a case report
The report focuses on two main aspects regarding a safe and sufficient usage of CytoSorb<sup>®</sup> in the intensive care medicine. First, shortened changing periods increase the elimination rate of the adsorber, which is quickly saturated by bigger molecules, for example, bile acids. Second, additional vancomycin dosing during CytoSorb<sup>®</sup> application avoids under dosing since CytoSorb<sup>®</sup> eliminates vancomycin.
Authors
- Michael Irlbeck (ORCID: https://orcid.org/0000-0002-7868-265X)
- Caroline Gräfe (ORCID: https://orcid.org/0000-0003-4580-5630)
- Helen Graf (ORCID: https://orcid.org/0009-0004-5185-7749)
- Christina Scharf (ORCID: https://orcid.org/0000-0002-5310-4116)
- Michael Paal (ORCID: https://orcid.org/0000-0001-8831-0238)
- Uwe Liebchen (ORCID: https://orcid.org/0000-0002-4375-0923)
Institutions
- LMU Klinikum (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Journal of Medical Case Reports
- Published
- 2025-09-08
- DOI
- https://doi.org/10.1186/s13256-025-05503-9
- Primary Topic
- Potassium and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00